Sanofi focuses on rare diseases and buys Inhibrx for 2.2 billion dollars

2 min read


Acquisition in the USA

The agreement was approved unanimously by the boards of directors of the two companies. New Inhibrx will continue to operate under the Inhibrx name, led by founder and CEO Mark P. Lappe as president and CEO

At five years old from the purchase of the American Synthorxthe French pharmaceutical giant Sanofi focuses on rare diseases and acquires Inhibrx, another US pharmaceutical company. Ace of the sleeve of the company based in La Jolla, California: Inbrx-101, a promising therapy against alpha-1 antitrypsin deficiency (Aatd), an inherited orphan disease that damages the lungs. Under the agreement – worth approximately $2.2 billion – Sanofi will acquire Inhibrx following the spin-off of the ‘non-Inbrx-101’ assets into New Inhibrx, in which Sanofi will retain an 8 percent stake.

Rare diseases: spending must become effective

Inbrx-101 is a human recombinant protein that promises patients with Aatd, a disease characterized by low levels of the Aat protein, to normalize them with a monthly rather than weekly dosage. Inbrx-101 would help reduce inflammation and prevent further impairment of lung function. Phase 1 clinical trials have been successfully completed and enrollment for phase 2 is underway. The agreement was unanimously approved by the boards of directors of the two companies. New Inhibrx will continue to operate under the Inhibrx name, led by founder and CEO Mark P. Lappe as president and chief executive officer.



Source link

You May Also Like

More From Author

+ There are no comments

Add yours